UK Women’s Health Market Size & Outlook, 2023-2030
UK women’s health market, 2018-2030 (US$M)
Related Markets
UK women’s health market highlights
- The UK women’s health market generated a revenue of USD 1,934.4 million in 2023 and is expected to reach USD 3,031.4 million by 2030.
- The UK market is expected to grow at a CAGR of 6.6% from 2024 to 2030.
- In terms of segment, contraceptives was the largest revenue generating application in 2023.
- Endometriosis & Uterine Fibroids is the most lucrative application segment registering the fastest growth during the forecast period.
Women’s health market data book summary
| Market revenue in 2023 | USD 1,934.4 million |
| Market revenue in 2030 | USD 3,031.4 million |
| Growth rate | 6.6% (CAGR from 2023 to 2030) |
| Largest segment | Contraceptives |
| Fastest growing segment | Endometriosis & Uterine Fibroids |
| Historical data | 2018 - 2022 |
| Base year | 2023 |
| Forecast period | 2024 - 2030 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Hormonal Infertility, Contraceptives, Postmenopausal Osteoporosis, Endometriosis & Uterine Fibroids, Menopause, Polycystic Ovary Syndrome (PCOS) |
| Key market players worldwide | AbbVie Inc, Bayer AG, Merck & Co Inc, Pfizer Inc, Teva Pharmaceutical Industries Ltd, Agile Therapeutics Inc, Amgen Inc, Apothecus, Blairex Laboratories, Ferring |
Other key industry trends
- In terms of revenue, UK accounted for 4.4% of the global women’s health market in 2023.
- Country-wise, U.S. is expected to lead the global market in terms of revenue in 2030.
- In Europe, Germany women’s health market is projected to lead the regional market in terms of revenue in 2030.
- UK is the fastest growing regional market in Europe and is projected to reach USD 3,031.4 million by 2030.
Contraceptives was the largest segment with a revenue share of 28.73% in 2023. Horizon Databook has segmented the UK women’s health market based on hormonal infertility, contraceptives, postmenopausal osteoporosis, endometriosis & uterine fibroids, menopause, polycystic ovary syndrome (pcos) covering the revenue growth of each sub-segment from 2018 to 2030.
The NHS has identified the average age of menopause in women as 51 years in the UK, except for women who enter menopause before 40 years of age or even in their 30s. It estimated that around 13 million women, or around one-third of the female population in the UK, were perimenopausal or menopausal.
Considering the large target population, researchers are innovating products to ease the transition of women through menopause. The high demand for women’s health drugs and devices in this country is responsible for its current market share. Moreover, the UK has a large population of young women.
According to the World Bank, in 2022, 21.2 million women are in the age group of 15 to 64 years in the country. This large demographic substantially increases the demand for women’s health products and treatments related to contraceptives, hormonal infertility, endometriosis, polycystic ovary syndrome, and others.
No credit card required*
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Women’s Health Market Scope
Women’s Health Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|
UK women’s health market size, by application, 2018-2030 (US$M)
UK Women’s Health Market Outlook Share, 2023 & 2030 (US$M)
Related industry reports
Related regional statistics
Sign up - it's easy, and free!
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
